Acadian Asset Management
EPRX

Acadian Asset Management’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Acadian Asset Management’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-93,600
Closed -$671K – 2288
2026
Q1 		$671K Sell
93,600
-62,166
-40% -$500K ﹤0.01% 1284
2025
Q4 		$1.17M Buy
155,766
+134,366
+628% +$828K ﹤0.01% 1077
2025
Q3 		$125K Buy
+21,400
New +$116K ﹤0.01% 1478

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Acadian Asset Management's EPRX Position: Q2 2026 in Review

Acadian Asset Management sold out of Eupraxia Pharmaceuticals (EPRX) in Q2 2026, closing a stake of 93,600 shares — an estimated $671K sold.

Acadian Asset Management first reported a position in EPRX in Q3 2025 and held it in 3 quarters. The position peaked at $1.17M in Q4 2025. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Acadian Asset Management reported no remaining Eupraxia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Acadian Asset Management sold 93,600 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $671K.
  • Acadian Asset Management first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Acadian Asset Management's Eupraxia Pharmaceuticals position peaked at $1.17M in Q4 2025.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.